Short-Term Debt to Capital: Biomerica Inc. (BMRA)
The Biomerica, Inc. (BMRA) market price chart reflects the performance of a defensive sector company whose demand remains independent of GDP fluctuations. The current value of the metric is 0.23. The business leverages years of experience in developing high-precision gastrointestinal research, earning recognition from physicians. Competent management, focused on US expansion and strict compliance with all government regulations, ensures a stable development trajectory.
Analytical breakdowns for Biomerica, Inc.
Global supply chain risks for Biomerica, Inc. diagnostic test components necessitate strict liquidity control; therefore, calculating the short-term liabilities-to-equity ratio via the value 0.23 allows for an assessment of the company's ability to settle urgent debts using its own assets, which is reflected in the trend of short-term loan volumes relative to equity to identify hidden financial vulnerabilities.